BMS-795311

BMS-795311 is an orally bioavailable small-molecule inhibitor of cholesteryl ester transfer protein (CETP) developed by Bristol Myers Squibb as a potential therapy to raise high-density lipoprotein cholesterol (HDL-C) and modify cardiovascular risk.[1][5][7][11] It potently inhibits CETP activity with low nanomolar IC50 values in biochemical assays and effectively blocks cholesteryl ester transfer in plasma, leading to increased HDL-C content and particle size in human CETP transgenic animal models, with efficacy comparable to earlier CETP inhibitors such as torcetrapib but without the same off-target blood pressure and aldosterone liabilities in preclinical testing.[5][8][9][11] BMS-795311 was partnered with Simcere Pharmaceutical Group for co-development in China, with the intent to explore its use in treating and preventing progression of cardiovascular disease, but it has remained at the preclinical/early development stage and has not advanced to late-stage clinical development or approval.[7][11][12][13]

Other names

BMS 795311BMS795311BMS-795311